Skip to contentN
Neogenomics Inc
N
NEONeogenomics Inc Q2 2025 · 10-Q
Revenue$181.33M$181.33M+10.2% vs Q2 2024 Net Income-$45.09M-$45.09MN/M vs Q2 2024 EPS Diluted-$0.35-$0.35N/M vs Q2 2024 Gross Profit$77,258,000+6.6% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Neogenomics Inc · CIK 1077183 · Engraved from SEC EDGAR
Operating Cash Flowderived$20,330,000+46.3% Free Cash Flowderived$14,007,000+1,620.8% Margins · derivedGross margin42.6%−1.5 pt vs Q2 2024
Operating margin-26.3%−12.9 pt vs Q2 2024
Net margin-24.9%−13.5 pt vs Q2 2024
ended Jun 30, 2025 · filed Jul 29, 2025 · 29 d after period end